Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 180

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Platelet Membrane Receptor Glycoprotein IIb/IIIa Antagonism in Unstable Angina: The Canadian Lamifiban Study

The´roux, Pierre, Kouz, Simon, Roy, Louis, Knudtson, Merril L., Diodati, Jean G., Marquis, Jean-Franc¸ois, Nasmith, James, Fung, Anthony Y., Boudreault, Jean-Rock, Delage, Franc¸ois, Dupuis, Robert, Kells, Catherine, Bokslag, Marianne, Steiner, Beat, Rapold, Hans J.·1996·Circulation

Abstract

Background Ligand binding to the platelet membrane receptor glycoprotein (GP) IIb/IIIa, the final and obligatory step to platelet aggregation, can now be inhibited by pharmacological agents. This study was designed to evaluate the potential of lamifiban, a novel nonpeptide antagonist of GP IIb/IIIa, for the management of unstable angina. Methods and Results In a prospective, dose-ranging, double-blind study, 365 patients with unstable angina were randomized to an infusion of 1, 2, 4, or 5 μg/min of lamifiban or of placebo. Treatment was administered for 72 to 120 hours. Outcome events were measured during the infusion period and after 1 month. Concomitant aspirin was administered to all patients and heparin to 28% of patients. Lamifiban, all doses combined, reduced the risk of death, nonfatal myocardial infarction, or the need for an urgent revascularization during the infusion period from 8.1% to 3.3% ( P =.04). The rates were 2.5%, 4.9%, 3.3%, and 2.4% with increasing doses. At 1 month, death or nonfatal infarction occurred in 8.1% of patients with placebo and in 2.5% of patients with the two high doses ( P =.03). The highest dose of lamifiban additionally prevented the need for an urgent intervention. Lamifiban dose-dependently inhibited platelet aggregation. Bleeding times were significantly prolonged with platelet inhibition of >80%. Major (but neither life-threatening nor intracranial) bleedings occurred in 0.8% of patients with placebo and 2.9% with lamifiban. Conclusions The nonpeptide GP IIb/IIIa antagonist lamifiban protected patients with unstable angina from severe ischemic events during a 3- to 5-day infusion and reduced the incidence of death and infarction at 1 month, suggesting considerable promise for this new therapeutic approach.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.94.5.899

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 180

Metadata

Authors
The´roux, P., Kouz, S., Roy, L., Knudtson, M. L., Diodati, J. G., Marquis, J.-F., Nasmith, J., Fung, A. Y., Boudreault, J.-R., Delage, F., Dupuis, R., Kells, C., Bokslag, M., Steiner, B., & Rapold, H. J.
Venue
Circulation
Published
1996-09
Volume
94
Issue
5
Pages
899-905
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2059312457
Cited by
180
References
1
FWCI
30.36
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Platelet Membrane Receptor Glycoprotein IIb/IIIa Antagonism in Unstable Angina: The Canadian Lamifiban Study. https://app.cochat.ai/papers/10.1161/01.cir.94.5.899
The paper
The´roux, P., Kouz, S., Roy, L., Knudtson, M. L., Diodati, J. G., Marquis, J.-F., Nasmith, J., Fung, A. Y., Boudreault, J.-R., Delage, F., Dupuis, R., Kells, C., Bokslag, M., Steiner, B., & Rapold, H. J. (1996). Platelet Membrane Receptor Glycoprotein IIb/IIIa Antagonism in Unstable Angina: The Canadian Lamifiban Study. Circulation. https://doi.org/10.1161/01.cir.94.5.899

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.